Biomea Fusion reports Phase 1 BMF-650 results, with weight reduction and safety data from its oral GLP-1 drug trial.
2026-10-14. The following slide deck was published by Biomea Fusion, Inc.
Biomea Fusion shares rise after-hours before Phase I results for oral GLP-1 candidate BMF-650.
Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings (NASDAQ:ITOC) shares
Biomea Fusion (BMEA) shares were down over 19% in Wednesday trading after the company said it termin
Biomea Fusion stock falls after ending a public securities offering and revising clinical data timelines for its obesity trial.
Biomea Fusion shares fall nearly 19% after hours, highlighting volatility in BMEA after Tuesday's session.
Biomea Fusion (BMEA) said late Tuesday it has commenced an underwritten public offering of its commo
SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Biomea intends to grant the underwriter a 30-day option to purchase up to an additional fifteen percent (15%) of the total numb
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that members of its management team will participate in the following upcoming investor conferences: Citi's 2026 Biopharma Back to School Conference: Biomea will participate in one-on-one investor meetings on September 10, 2026, in New York, NY.H.C. Wainwright 28th Annual Global Investment Confere
Topline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes (“T2D”) patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated in the first quarter of 2027COVALENT-212 Phase II enrollment T2D patients who are not achieving glycemic targets despite GLP-1 based therapy is still ongoing, with topline 26-week primary endpoint data anticipated in the second quarter of 2027These ongoing Phase II diabetes trials target two distinct
Biomea Fusion (BMEA) shares rose over 14% in Monday trading after the firm said it has completed enr
This is the newest page. Registered accounts read further back.